Netflix Model Could Make $28K HIV Prevention Drug Free

A medical breakthrough that could help end the HIV epidemic is sitting on the shelf because almost no one can afford it.

Lenacapavir, a twice-yearly injection, showed zero HIV infections among over 2,000 young women in a groundbreaking trial. The drug works better than daily pills and protects men and gender-diverse people just as effectively. But at $28,218 per person per year, insurance companies have blocked access and clinics can't afford to stock it.

Dr. Michael Rose, an internist at Johns Hopkins, says we've seen this movie before. Another injectable HIV prevention drug, cabotegravir, launched four years ago with similar promise. Today it represents less than 3% of HIV prevention use in the United States because of its $21,000 price tag.

But there's a proven solution that worked for another expensive cure. When hepatitis C drugs launched at $84,000 per patient, Louisiana, Washington state, and Australia tried something different. They paid drug makers a flat subscription fee for unlimited access, like paying for Netflix instead of buying individual movies.

The results speak for themselves. Louisiana saw hepatitis C prescriptions jump fivefold. Australia cut hepatitis C deaths nearly in half and saved money over time. The drug companies stayed profitable while per-patient costs plummeted.

Lenacapavir is perfectly suited for this approach. Manufacturing costs are estimated at just $25 per year, meaning there's room for drug makers to profit while making the drug accessible. The company that makes lenacapavir already participated in hepatitis C subscription agreements, so they know how it works.

The Ripple Effect

Subscription pricing eliminates the biggest barrier to HIV prevention: cost per patient. Insurers pay a predictable amount. Clinics can stock the drug without worrying about upfront costs. Patients get protection that actually works.

The model has bipartisan support because it aligns business realities with public health needs. Even countries with government-negotiated drug prices have benefited from subscription models. While generic lenacapavir is already available in low-income countries, subscription pricing could expand access in middle-income nations.

The current approach to innovative drugs follows a depressing pattern: breakthrough discovery, sky-high prices, restricted access, then years of waiting while availability slowly expands. Hepatitis C proved we don't have to accept that timeline.

With HIV prevention, we have a drug that works 100% of the time sitting unused because of an outdated payment system. Subscription pricing offers a faster path to actually ending the HIV epidemic, not just talking about it.